BIO-RAD LABORATORIES, INC.
No SEC Form 4 filings for $BIO in the last 30 days.
Bio-Rad Laboratories’ Q2 2026 earnings call cited 10% sequential revenue growth, with year-over-year pressure from softer academic research and cautious biopharma demand. Management reaffirmed full-year currency-neutral revenue guidance of -3% to +0.5% and expects ddPCR instrument revenue up 20% and $30m to $35m net annual savings by 2027.
Bio-Rad Laboratories (BIO) said Q2 demand from academic and government customers stayed below historical levels, especially in the Americas, though NIH outlays are rising. It reported stabilization signs in biopharma, with China revenue down in the high teens and a ~$4M H2 headwind. Q2 non-GAAP EPS was $2.62. Gross margin was 53.1%. Bio-Rad reaffirmed 2026 guidance and announced restructuring with $30M-$35M annualized savings.
BIO-RAD LABORATORIES, INC. (BIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bio-8k842026xex991.htm EX-99.1 Document Exhibit 99.1 Press Release Bio-Rad Reports Second -Quarter 2026 Financial Results HERCULES, Calif.—August 4, 2026 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnosti
Over the past 7 days, alphai's AI scored 3 news stories mentioning BIO (BIO-RAD LABORATORIES, INC.). Coverage has been balanced: 0 bullish, 3 neutral, and 0 bearish.
Recent BIO coverage spans financial news and earnings.
Guidance reaffirmation plus restructuring and ddPCR growth drivers likely shift near-term expectations for margins and recurring consumables timing.
Earnings call highlights point to uneven demand by region, modest margin pressure year over year, and a restructuring plan aimed at 2027 operating-margin expansion.
The quarter shows segment divergence (Clinical Diagnostics growth offset by Life Science softness) while guidance is reaffirmed, making the key trade the durability of Clinical Diagnostics and cash generation.
Citigroup's downgrade of BIO to Neutral with a lowered price target indicates short-term caution, primarily due to process chromatography and Chinese diagnostics concerns. Despite recent portfolio expansion, the outlook remains cautious.
Bio-Rad Laboratories experienced a over 3% drop, with the article suggesting limited near-term fundamental improvements.
alphai scores every news story that mentions BIO with an AI model for sentiment and relevance, and aggregates insider trades from BIO-RAD LABORATORIES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bio-Rad Laboratories’ Q2 2026 earnings call cited 10% sequential revenue growth, with year-over-year pressure from softer academic research and cautious biopharma demand. Management reaffirmed full-year currency-neutral revenue guidance of -3% to +0.5% and expects ddPCR instrument revenue up 20% and $30m to $35m net annual savings by 2027.
6 min readBio-Rad Laboratories (BIO) said Q2 demand from academic and government customers stayed below historical levels, especially in the Americas, though NIH outlays are rising. It reported stabilization signs in biopharma, with China revenue down in the high teens and a ~$4M H2 headwind. Q2 non-GAAP EPS was $2.62. Gross margin was 53.1%. Bio-Rad reaffirmed 2026 guidance and announced restructuring with $30M-$35M annualized savings.
6 min readBIO-RAD LABORATORIES, INC. (BIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bio-8k842026xex991.htm EX-99.1 Document Exhibit 99.1 Press Release Bio-Rad Reports Second -Quarter 2026 Financial Results HERCULES, Calif.—August 4, 2026 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnosti
6 min readCitigroup has lowered its rating on Bio-Rad Laboratories (BIO) to Neutral and reduced its price target from $375 to $300, citing concerns over the company's process chromatography segment and diagnostic operations in China. Despite this, Bio-Rad recently expanded its portfolio of recombinant monoclonal anti-idiotypic antibodies, enhancing its capabilities in drug development and monitoring. The article suggests that while Bio-Rad has investment potential, other AI stocks may offer greater upside with less risk.
3 min readThe company doesn't seem like it will generate pops in key fundamentals anytime soon.
3 min readBio-Rad (BIO) delivered earnings and revenue surprises of -1.74% and +0.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readBio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 min readBiodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testing Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testing ...
2 min readLOUISVILLE, Colo., Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Biodesix, Inc. ( NYSE:BDSX ) , a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and regulatory submissions of in ...
3 min readBIO's strong ddPCR growth and solid diagnostics demand support its stock despite market pressures and stiff competition.
4 min read
